贝伐单抗联合奥沙利铂和阿霉素或脂质体阿霉素治疗肝细胞癌：病例系列
Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: a case series.
作者信息
Ku Geoffrey Y, De Lima Lopes Gilberto, Chang Alex Y
机构信息
Johns Hopkins Singapore International Medical Centre, Singapore.
出版信息
Asia Pac J Clin Oncol. 2011 Jun;7(2):174-9. doi: 10.1111/j.1743-7563.2010.01345.x. Epub 2010 Dec 22.
AIMS
Despite the emergence of sorafenib as the standard treatment for patients with advanced hepatocellular cancer (HCC), therapy remains sub-optimal and toxic.
METHODS
We report on five patients with advanced HCC treated with bevacizumab, oxaliplatin and doxorubicin or liposomal doxorubicin.
RESULTS
Of the five patients, four had cirrhosis; two patients had Child-Pugh A cirrhosis, while one each had Child-Pugh B and C cirrhosis. Grade 3/4 toxicity was uncommon. Four patients had a decrease of ≥50% in alpha-fetoprotein levels following therapy and one patient each had a radiographic complete response and stable disease.
CONCLUSION
These data add to the growing phase II data that bevacizumab-containing regimens are active in advanced HCC patients. Further evaluation of regimens containing bevacizumab with oxaliplatin and/or doxorubicin may be warranted.
目的
尽管索拉非尼已成为晚期肝细胞癌（HCC）患者的标准治疗药物，但该疗法仍存在不足且有毒性。
方法
我们报告了5例接受贝伐单抗、奥沙利铂和阿霉素或脂质体阿霉素治疗的晚期HCC患者。
结果
5例患者中，4例有肝硬化；2例为Child-Pugh A级肝硬化，1例为Child-Pugh B级肝硬化，1例为Child-Pugh C级肝硬化。3/4级毒性并不常见。4例患者治疗后甲胎蛋白水平下降≥50%，1例患者影像学检查完全缓解，1例病情稳定。
结论
这些数据进一步补充了越来越多的II期数据，表明含贝伐单抗的方案对晚期HCC患者有效。可能有必要进一步评估含贝伐单抗与奥沙利铂和/或阿霉素的方案。
Zotero 插件